Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04318977

rTMS Add on Value for Amelioration of Negative Symptoms of Schizophrenia

Treatment of depression with repetitive transcranial magnetic stimulation (rTMS) has shown high evidence using high-frequency left dorsolateral prefrontal cortex (DLPFC) stimulation. The treatment of negative symptoms with the same protocol in schizophrenia is considered as possible effective. Theta burst stimulation is a new protocol which is characterized by shorter sessions showing first evidence that it's efficacy is comparable to the high-frequency rTMS. In this randomized placebo-controlled study the efficacy of high-frequency rTMS and TBS are evaluated.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Brno University Hospital, Brno, Czechia

Loading trial locations.

About this study

In this randomized placebo-controlled study the efficacy of high-frequency rTMS and TBS are evaluated. The active study arms are high-frequency rTMS and iTBS of the left dorsolateral prefrontal cortex to treat negative symptoms in schizophrenia. The control arm will include the same number of patients as each active arm and includes both sham rTMS and sham iTBS in the same proportion as the active treatments.

Standards of the trial will be harmonized across four clinical centers with the aim to pool data for analysis. Each center is responsible for ethical approval and adherence to good clinical practice by itself (Sponsor).

Interim analysis: Several meta-analyses of the effect of rTMS/iTBS on negative symptoms in schizophrenia showing heterogeneous effect sizes have been published since begin of the trial. Thefore, an interim analysis after inclusion of at least 15 patients in each arm was added to the protocol. In case of null findings and low effect sizes (no differences of either rTMS or TBS vs. sham in the primary outcome), the trial will be terminated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ICD-10: schizophrenia with primarily negative symptoms
  • Age: 18-75 years
  • at least 35 Points at the composite score of the SANS
  • stabe medication during the last 2 weeks (at the investigator's discretion)
  • written informed consent (by the patient or guardian)

Exclusion criteria

  • clinically relevant unstable concomitant somatic diseases
  • previous treatment by rTMS
  • conditions in which TMS may not be applicated, as e.g., cardiac pacemakers or ferromagnetic implants
  • history of epileptic seizures
  • current substance or alcohol abuse, or clinically relevant comorbidity (according to M.I.N.I. interview)
  • unacceptable concomitant medication (benzodiazepines in higher doses, e.g., Lorazepam > 2 mg/d, Diazepam > 10 mg/d)
  • insufficient knowledge of the language of the country of the treatment site
  • pregnancy and nursing period
  • current statutory hospitalisation

Treatment and study plan

High-frequency rTMS

Device

repetitive transcranial magnetic stimulation

TBS

Device

theta burst stimulation

PLACEBO

Device

placebo transcranial magnetic stimulation

Primary outcomes

  1. Scale for the Assessement of Negative Symptoms (SANS)

    Time frame: 4 weeks

    negative symptoms in schizophrenia with 25 items and a range 0-125 with higher score representing more symptoms

Secondary outcomes

  1. Scale for the Assessement of Negative Symptoms (SANS)

    Time frame: 2 weeks, 4 weeks, 12 weeks

    negative symptoms in schizophrenia with 25 items and a range 0-125 with higher score representing more symptoms

  2. Positive and Negative syndrome scale (PANSS)

    Time frame: 2 weeks, 4 weeks, 12 weeks

    positive and negative symptoms in schizophrenia with 30 items and a range 30-210 with higher scores representing more symptoms (total score, score for positive, negative symptoms and for general psychopathology)

  3. Calgary Depression Scale for Schizophrenia (CDSS)

    Time frame: 2 weeks, 4 weeks, 12 weeks

    Calgary Depression Scale for Schizophrenia

  4. Clinical global impression (CGI)

    Time frame: 2 weeks, 4 weeks, 12 weeks

    measure of overall symptom severity and treatment response on a scale 1-7 with higher scores presenting more symptoms

  5. Major Depression Inventory (MDI)

    Time frame: 2 weeks, 4 weeks, 12 weeks

    measurment of depressivity: 10 items with a range 0-50 and higher values indicating higher scores

  6. Hamilton depression rating scale (HDRS)

    Time frame: 2 weeks, 4 weeks, 12 weeks

    measurment of depressivity: 21 items with a range 0-65 and higher values indicating higher scores

  7. Memory span test (digit span)

    Time frame: 4 weeks, 12 weeks

    test for short-term and working memory

  8. test of attention (d2)

    Time frame: 4 weeks, 12 weeks

    test of attention for measurement of concentration

  9. Resting state electroencephalogram (EEG)

    Time frame: 4 weeks

    measurement of resting state electrophysiologic activity as indicated by frequency analysis and rTMS-evoked activity

  10. magnetic resonance imaging (MRI)

    Time frame: 4 weeks

    structural, anatomical, diffusion weighted magnetic resonance imaging

  11. cigarettes

    Time frame: 4 weeks, 12 weeks

    number of smoked cigarettes per week

Sponsors and collaborators

Lead sponsor

University of Regensburg

Other

Collaborators

  • Brno University Hospital
  • University Hospital Ostrava
  • University Hospital, Aachen

Registry information

Acronym: RADOVAN

Important dates

Study start
2020
Primary completion
2024
Study completion
2025
First posted
Mar 24, 2020
Registry last updated
Sep 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.